GERMPRO version 02
Research type
Research Study
Full title
Drivers of aggression in germline BRCA2-mutated prostate cancer
IRAS ID
258662
Contact name
Robert Bristow
Contact email
Sponsor organisation
University of Manchester
Clinicaltrials.gov Identifier
N/A, N/A
Duration of Study in the UK
10 years, 0 months, 0 days
Research summary
The risk of early onset and aggressive prostate cancer (PC) is increased in men with hereditary BRCA2 mutations. Additionally, men who are carriers of BRCA2 mutations more frequently fail standard of care therapies and have worse overall clinical outcomes than men with sporadic prostate cancer. The aim of the study is to characterise the morphological features of these specimens and assess their significance in prostate cancer progression. In addition we aim to interrogate the biological program within the tumour samples by DNA/RNA-based sequencing analysis in order to understand the progression of the disease. This will lead to a significant step-change in understanding the pathology of this disease. This study will achieve this through the use of previously collected FFPE (formalin-fixed and paraffin embedded) human prostate tissue.
REC name
East Midlands - Nottingham 2 Research Ethics Committee
REC reference
19/EM/0136
Date of REC Opinion
2 May 2019
REC opinion
Favourable Opinion